

## C L A I M S

1. A method for the diagnosis of ABPA in a human individual,  
5 **characterized** by determining if the individual carries  
antibodies reactive with one or more ABPA-related  
recombinant allergens.
2. The method according to claim 1, **characterized** in that the  
10 allergen is derived from *A. fumigatus*.
3. The method according to claim 2, **characterized** in that the  
allergen correspond to a non-secreted protein from *A.*  
*fumigatus*.  
15
4. The method according to anyone of claims 1-3,  
**characterized** in that said one or more allergens are  
selected among rAsp f4 and rAsp f6 and ABPA-related  
fragments thereof.
- 20 5. The method according to anyone of claims 1-3,  
**characterized** in that said one or more allergens are  
selected among rAsp f8 and ABPA-related fragments thereof.
- 25 6. The method according to anyone of claims 1-4,  
**characterized** in that an in vitro immunoassay is carried  
out on a fluid sample from the individual for the  
determination of the level of antibodies directed towards  
said recombinant allergens, in particular antibodies of  
30 the IgE class or IgG class or subclasses thereof.
7. The method according to anyone of claims 1-5,  
**characterized** in that antibodies of the IgE class are  
determined.

8. The method according to anyone of claims 1-4, **characterized** in that an in vivo test is carried out in the individual.
- 5 9. The method according to claim 7, **characterized** in that the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.
- 10 10. The method according to claim 5, **characterized** in that an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens, in particular antibodies of the IgE class or IgG class or subclasses thereof.
- 15 11. The method according to claim 10, **characterized** in that antibodies of the IgE class are determined.
- 20 12. The method according to claim 5, **characterized** in that an in vivo test is carried out in the individual.
13. The method according to claim 12, **characterized** in that the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.

und G1

Added C107